NRGN and Alzheimer disease: Ng peptides ending at −75 have been targeted using a sandwich ELISA (De Vos et al., 2016) and shown to be already elevated in CSF of patients with mild cognitive impairment (MCI) with a high probability for AD (MCI patients).